The FDA on April 16, 2021 approved OPDIVO® (Nivolumab) in combination with Fluoropyrimidine- and Platinum-containing chemotherapy for advanced or metastatic Gastric cancer, Gastroesophageal Junction cancer, and Esophageal adenocarcinoma. OPDIVO® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
